title: Immediate changes in lung compliance following natural surfactant administration in premature infants with respiratory distress syndrome: a controlled trial.
abstract: OBJECTIVE
  To compare immediate changes in lung compliance following the administration of two commercially available natural surfactants.
  
  
  METHODS
  We conducted a prospective, randomized study of 40 preterm infants with respiratory distress syndrome requiring surfactant. Infants received either Infasurf or Survanta. The primary outcome measure was the change in compliance assessed by bedside pulmonary monitoring.
  
  
  RESULTS
  There were no significant changes in dynamic lung compliance within or between the two groups 1 hour after surfactant administration. However, infants given Survanta required more doses per patient (4 vs 2, p=0.05) and were more likely to require >2 doses (57 vs 26%, p=0.05). Infants requiring >1 dose of surfactant had a greater change in airway pressure and improved oxygenation just before the second dose when treated with Infasurf.
  
  
  CONCLUSIONS
  We found no significant difference in acute changes in lung compliance. However, treatment with Infasurf seems to be more long lasting than Survanta.
authors.affiliation: Department of Pediatrics and Communicable Diseases, University of Michigan, MI, USA.
authors.forename: Mohammad A
authors.initials: MA
authors.lastname: Attar
authors.forename: Michael A
authors.initials: MA
authors.lastname: Becker
authors.forename: Ronald E
authors.initials: RE
authors.lastname: Dechert
authors.forename: Steven M
authors.initials: SM
authors.lastname: Donn
mesh_terms: D001688:Biological Products / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D008170:Lung Compliance / Q000187:drug effects*; D011336:Probability; D011446:Prospective Studies; D011663:Pulmonary Surfactants / Q000627:therapeutic use*; D012016:Reference Values; D012127:Respiratory Distress Syndrome, Newborn / Q000175:diagnosis* / Q000188:drug therapy*; D012129:Respiratory Function Tests; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D001688:Biological Products; D011663:Pulmonary Surfactants; C117342:calfactant; C072197:beractant